Learn more about the similarities and difference between biosimilars and reference products and how to integrate biosimilars into your practice.
Learn innovative strategies for psoriasis care with telemedicine.
Through a robust Delphi process, IPC’s network of experts developed a consensus statement that redefines the criteria for patients who are candidates for systemic therapy.
Navigate the landscape of psoriasis in individuals with diverse skin types, understanding its distinct presentation and addressing challenges in access to care, diagnosis, and treatment.
A clinical education tool to help with accurately diagnosing and assessing psoriasis in people with darker skin can be challenging, as many dermatology references often fail to capture the full range of presentations in diverse skin types.
Detect the nuances of GPP, recognize its symptoms, and uncover treatment options.
A compilation of evidence-based guidelines for psoriasis diagnosis and management.
Learn about infectious diseases and their impact on psoriasis care.
Biblioteca de todos los artículos, informes de congresos, publicaciones y videos del IPC disponibles en español publicados en los últimos dos años.
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
